Brief: Pharmala Biotech Executes Definitive Agreement To Form Special Purpose Vehicle, Restora Neurosciences, For Clinical Development Of Patented Novel Mdxx Molecule Apa-01
13/05/2026 13:37
May 13 (Reuters) - Pharmala Biotech Holdings Inc MDMA.CD: PHARMALA BIOTECH EXECUTES DEFINITIVE AGREEMENT TO FORM SPECIAL PURPOSE VEHICLE, RESTORA NEUROSCIENCES, FOR CLINICAL DEVELOPMENT OF PATENTED NOVEL MDXX MOLECULE APA-01 PHARMALA BIOTECH HOLDINGS INC - CO AND ALUVARIS TO EACH HOLD 50% OF RESTORA NEUROSCIENCES SPV PHARMALA BIOTECH HOLDINGS INC - RESTORA TO PAY PHARMALA $500,000 ONE-TIME LICENSE FEE UPON FUNDING THRESHOLD PHARMALA BIOTECH HOLDINGS INC - LICENSE BECOMES FINAL WHEN RESTORA RAISES AT LEAST $2.5 MILLION IN CASH SUBSCRIPTIONS PHARMALA BIOTECH HOLDINGS INC - TO GRANT RESTORA EXCLUSIVE WORLDWIDE ROYALTY-BEARING LICENSE FOR APA-01 PHARMALA BIOTECH HOLDINGS INC - TO RECEIVE 3% PERPETUAL ROYALTY ON NET SALES OF LICENSED PRODUCTS Source text: ID:nGNX2SJrbD Further company coverage: MDMA.CD ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmala Biotech Holdings
See all newsBrief: Pharmala Biotech Executes Definitive Agreement To Form Special Purpose Vehicle, Restora Neurosciences, For Clinical Development Of Patented Novel Mdxx Molecule Apa-01
Brief: Pharmala Executes Binding Letter Of Intent For Formation Of Special Purpose Vehicle To Develop Patented Novel Mdxx Molecule Apa-01
Brief: PharmALa Signs Supply & Data Agreement With Nautilus Sanctuary For Phase 2 Mdma Clinical Trial Treating Post-Traumatic Stress And Adjustment Disorder In Frontline Healthcare Workers And First Responders
Brief: Pharmala Delivers MDMA To Merhavim Mental Health Centre Clinical Trial In Exchange For Full Data License
Brief: Pharmala Issues Q2 Financial Statements